Answers are grounded in this paper and cite their sources.
Polycystic ovary syndrome (PCOS) is a common disease among women of reproductive age, manifested by a wide range of hormonal and metabolic disorders. Since the exact etiology of PCOS is still unclear, available pharmacotherapy is mainly aimed at relieving symptoms and associated metabolic disorders. With the emergence of new data on the pathogenesis of the syndrome, other treatment methods are being developed. This publication is a review of current and new treatments for women with PCOS. As you know, the symptoms of this disease are very diverse. None of the available pharmacological treatment options can cover the entire spectrum of clinical manifestations observed in women with this pathology. Therefore, treatment must be individualized and adapted to the specific needs of each patient. The article reviews data on the use of various drugs for the correction of metabolic disorders. Information is provided on new approaches to treatment aimed at correcting neurohormonal regulation. Also analyzed are studies devoted to the study of innovative methods of therapy from the perspective of complex mechanisms of control of cellular activity, proliferation, apoptosis, which underlie pathogenesis. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The priority was free access to the full text of articles. The choice of sources was prioritized for the period from 2017 to 2023, however, the list of references contains several publications dating back to earlier years.
No takes yet. Share an insight, caveat, or question.
Absatarova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: